| Brand Name: Generic AVANDIA (Rosiglitazone Maleate) Generic Name: Rosiglitazone Maleate Drug Class: TREATMENT OF TYPE II DIABETES
INDICATIONS
Before initiation of therapy with Generic AVANDIA (Rosiglitazone Maleate), the secondary causes of the poor control glycemic, for example, infection contaminations, should be investigated and be treated. Thermal limitation, loses of weight, and exercise are essential for appropriate processing the diabetic patient because they help to improve sensitivity of an insulin. It is important not only on the main processing type 2 of diabetes, but also and in maintenance of efficacyy of medicinal therapy. Control of type 2 of diabetes should include the control of a diet.
Generic AVANDIA (Rosiglitazone Maleate) is designated as addition to a diet and exercise to improve the control glycemic at patients with phylum 2 diabetes.
- Generic AVANDIA (Rosiglitazone Maleate) also is designated for utilization in a combination with sulfonylurea plus metformin when a diet, exercise, and both ingredients do not result in the adequate control glycemic.
- For the patients inadequately controlled with a maximum dose sulfonylurea or metformin, Generic AVANDIA (Rosiglitazone Maleate) should be added to, instead of is replaced for, sulfonylurea or metformin. Generic AVANDIA (Rosiglitazone Maleate) also is designated for utilization in a combination with sulfonylurea, metformin, or an insulin when a diet, exercise, and unique an ingredient do not result in the adequate control glycemic.
- Generic AVANDIA (Rosiglitazone Maleate) is designated as monotherapy.
DOSAGE AND ADMINISTRATION
Generic AVANDIA (Rosiglitazone Maleate) can be taken with or without the foodstuffs.
Special Populations
Geriatric: Any adjustment of dosage is not required for elderly.
Renal Impairment: Any adjustment of dosage is not necessary when Generic AVANDIA (Rosiglitazone, maleate) is used as monotherapy at patients with renal damage. Since then metformin it is contraindicated in such patients, concomitant administration metformin and Generic AVANDIA (Rosiglitazone Maleate) also contraindicate at patients with renal damage.
Hepatic Impairment: Therapy with Generic AVANDIA (Rosiglitazone Maleate) should not be initiated, if the patient shows the clinical evidence to awake illness of a liver or enlarged serum levels of transaminase (the HIGH NOTE> 2.5X a upper bound normal in the beginning of therapy). The enzyme of the liver, monitoring is recommended at all patients before initiation of therapy with Generic AVANDIA (Rosiglitazone Maleate) and periodically after that.
Pediatric : The data are insufficient to recommend pediatric utilization Generic AVANDIA (Rosiglitazone Maleate).
Control of antidiabetic therapy should be individualized. All patients should begin Generic AVANDIA (Rosiglitazone Maleate) in the lowest recommended dose. Further augmentations in dose Generic AVANDIA (Rosiglitazone Maleate) should be accompanied by the careful control over the unfavorable events connected to fluid conservation.
Sulfonylurea: When routine launching dose Generic AVANDIA (Rosiglitazone Maleate) - 4 mg used or as a single dose once daily or in separate doses two times day is used in a combination with sulfonylurea. If patients report hypoglycemia, the dose sulfonylurea should be diminished.
Metformin: Routine launching dose Generic AVANDIA (Rosiglitazone Maleate) in a combination with metformin - 4 mg used or as a single dose once daily or in separate doses two times day. It is improbable, that the dose metformin will demand adjustment owing to hypoglycemia during the combined therapy with Generic AVANDIA (Rosiglitazone Maleate).
Insulin: For patients, stable on an insulin, the dose of an insulin should be continued after initiation of therapy with Generic AVANDIA (Rosiglitazone Maleate). Generic AVANDIA (Rosiglitazone Maleate) should be dosed in 4 mg daily. (Rosiglitazone Maleate) is more than dose Generic AVANDIA than 4 mg daily in a combination with an insulin now are not designated. It is recommended, that the dose of an insulin diminished by 10 % to 25 % if the patient reports hypoglycemia or if FPG concentrations decrease to less than 100 mg/dL. The further adjustment should be individualized based on reaction depressed glucose.
Sulfonylurea Plus Metformin: Routine launching dose Generic AVANDIA (Rosiglitazone Maleate) in a combination with sulfonylurea plus metformin - 4 mg used or as a dose once a day or separate doses two times day. If patients report hypoglycemia, the dose sulfonylurea should be diminished.
Maximum Recommended Dose: Dose Generic AVANDIA (Rosiglitazone Maleate) should not exceed 8 mg daily, as a single dose or separate two times day. A daily dose on 8 mg have shown to be safe and efficient on clinical researches as monotherapy and on a combination with metformin, sulfonylurea, or sulfonylurea plus metformin. (Rosiglitazone Maleate) is more than dose Generic AVANDIA than 4 mg daily in a combination with an insulin now are not designated.
Generic AVANDIA (Rosiglitazone Maleate) can be applied or in a launching dose of 4 mg as unique a daily dose or separates and to be applied in the morning and in the evening. For patients which answer inadequately during 8 - to 12 weeks of processing as it is specific by reduction FPG, the dose can be enlarged to 8 mg daily as monotherapy or in a combination with metformin, sulfonylurea, or sulfonylurea plus metformin. Reductions glycemic parameters are described by a dose and a regime under CLINICAL RESEARCHES. Generic AVANDIA (Rosiglitazone Maleate) can be taken with or without the foodstuffs.
Combination Therapy: When Generic AVANDIA (Rosiglitazone Maleate) is added to the existing therapy, the streaming dose(s) an ingredient(s) can be continued after initiation Generic AVANDIA (Rosiglitazone Maleate) therapy.
Monotherapy: Routine launching dose Generic AVANDIA (Rosiglitazone Maleate) - used 4 mg or as a single dose once daily or in separate doses two times day. On clinical experiments, two times day the regime has resulted 4 mg in the biggest reduction FPG and HbA1c. | 
